Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?

Expert Review of Clinical Immunology

Volumn 9, Issue 12, 2013, Pages 1155-1157

  De Groot, Anne S ^a,b  

^a EpiVax Inc   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Autoimmune disease; Immunoglobulin G; IVIg; Treg; Tregitope

Indexed keywords

EPITOPE; FC RECEPTOR; GLUTAMATE DECARBOXYLASE; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; REGULATORY T LYMPHOCYTE EPITOPE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SOMATIC HYPERMUTATION; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; T-LYMPHOCYTES, REGULATORY;

EID: 84887986948     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.858602     Document Type: Review

References (28)

1. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 28(11), 482-490 (2007
2. De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes." Blood 112(8), 3303-3311 (2008
3. De Groot AS, Martin W. Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clin. Immunol. 131(2), 189-201 (2009
4. Cousens LP, Jawa V, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin. Immunol. (2013) (In Press
5. De Groot AS, Terry F, Cousens LP, Martin W. Beyond Humanization and Deimmunization: Tolerization as a method for reducing the immunogenicity of biologics. Exp. Rev. Clin. Pharmacol. (2013) (In Press
6. Cousens LP, Tassone R, Mazer BD, Ramachandiran V, Scott DW, De Groot AS. Tregitope update: Mechanism of action parallels IVIg. Autoimmun. Rev. 12(3), 436-443 (2012
7. Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumorderived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787-2794 (2011
8. Ephrem A, Chamat S, Miquel C et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111(2), 715-722 (2008
9. Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J. Rheumatol. 39(5), 1019-1025 (2012
10. Schwab I, Nimmerjahn F Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat. Rev. Immunol. 13(3), 176-189 (2013
11. Soukhareva N, Jiang Y, Scott DW. Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: Role of T regulatory cells. Cell Immunol. 240, 41-46 (2006
12. Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: Our experience with a large cohort of patients. Autoimmunity 38(2):123-137 (2005
13. Jordan SC, Toyoda, M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: Relevance to solid organ transplantation. Expert Rev. Clin. Immunol. 7(3), 341-348 (2011
14. Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long-Term Therapy with Intravenous Immunoglobulin is Beneficial in Patients with Autoimmune Diseases. Clin. Rev. Allergy Immunol. 42(2), 247-255 (2012
15. Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: From the bench to the bedside. Lupus 18(10), 884-888 (2009
16. Dykes AC, Walker ID, Lowe GD, Tait RC. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: A 2-year review. Haemophilia 7(2), 160-163 (2001
17. Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin. Hematol. 46(1Suppl. 2), S2-S14 (2009
18. Lozeron P, Adams D. Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010. J. Neurol. 258(9), 1737-1741 (2011
19. Rajabally YA, Mahdi-Rogers M. Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins. Biologics 4, 45-49 (2010
20. Cousens LP, Najafian N, Mingozzi F et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity. J. Clin. Immunol. 33(1), 43-49 (2013
21. Cousens LP, Su Y, McClaine E et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J. Diabetes Res. 2013, 621693 (2013
22. Su Y, Rossi R, De Groot AS, Scott DW. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicityper se. J. Leukoc. Biol. 94(2), 377-383 (2013
23. Hui DJ, Basner-Tschakarjan E, Chen Y et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol Ther. 21(9), 1727-1737 (2013
24. Cousens LP, Mingozzi F, Van Der Marel S et al. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease. Hum. Vaccin. Immunother. 8(10), 1459-1464 (2012
25. Moise L, Gutierrez AH, Bailey-Kellogg C et al. The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix. Hum. Vaccin. Immunother. 9(7), 1577-1586 (2013
26. Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J. Immunol. 175(11), 7728-7737 (2005
27. Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc. Natl Acad. Sci. USA 103(23), 8810-8815 (2006
28. Sharabi A, Dayan M, Zinger H, Mozes E. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. J. Clin. Immunol. 30(1), 34-44 (2010